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Introduction
With over 200 million individuals affected every year and a third 
of all countries considered endemic, schistosomiasis remains 
one of the most widespread parasitic diseases on the planet. 
It is one of the world’s major global health problems, being 
responsible for 200,000 deaths annually1,2. Infections in humans 
are caused by five main species of platyhelminth parasites of the 
genus Schistosoma, of which S. mansoni and S. haematobium 
are the most prevalent. Infection in humans begins with the 
penetration of the skin by free-swimming cercariae, which 
triggers their transformation into schistosomula. After a few 
days of maturation in the dermis, these enter the bloodstream 
and progressively develop into male and female worms that 
pair up in the blood vessels of their host’s liver. Pairs ultimately 
migrate towards their final place of residence: the mesenteric 
vessels of the bowel in the case of species causing intestinal 
schistosomiasis, or the venous plexus of the bladder for 
Schistosoma haematobium, where female worms start laying 
eggs four to six weeks after infection. Despite the widespread 
incidence and debilitating effects of schistosomiasis in chroni-
cally infected patients, praziquantel is the only drug routinely 
used to treat established infections in populations living in 
endemic areas. The incomplete efficacy of the treatment, its 
lower efficiency at killing immature schistosomula and the 
increasing risk of drug resistance3 make the discovery of new 
therapeutics, and in particular vaccines, even more pressing4,5. 
Yet, despite many years of research, very few vaccine candidates 
have progressed to clinical trials6. Two S. mansoni antigens 
(Sm-14, Sm-TSP-2) are being tested in humans, while a third 
antigen, Sm-p80, should soon enter phase I studies7. In the case 
of S. haematobium, Sh28-GST has been the only clinically tested 
candidate against the urogenital form of the disease8.
The publication of the parasite’s genome9 and advances in 
transcriptional and proteomics studies10–18 have revealed many 
potential candidates whose protective effects are yet to be tested 
in animal models. Proteins secreted by the parasite or present 
on its surface are generally considered good vaccine candidates 
because of their direct accessibility to vaccine-induced antibod-
ies. The surface of the adult schistosome, however, is covered 
by a thick tegumental double phospholipid bilayer 
shielding the parasite from host antibodies and capturing host 
antigens19,20, allowing it to survive for many years, sometimes 
decades, in the vasculature of infected individuals10. Targeting 
the parasite at a different stage of its life cycle, when it could be 
more vulnerable to the host humoral immune system, has been 
proposed as a possible approach21.
Immediately after penetrating the skin, the early schistosomula 
undergo an extensive surface remodelling, leaving their external 
surface free of the dense glycocalyx that was covering them at 
the cercarial stage22. In support of this idea, infection of various 
animal models with irradiated cercariae can elicit immunologi-
cal protection to reinfection23,24, suggesting that the parasite is 
more susceptible to killing by the host in the first few days that 
follow infection. The use of attenuated parasites as a vaccine 
is, however, not suitable both in terms of practicability (they 
can be difficult to prepare and may suffer from batch-to-batch 
variations) and safety (each batch needs to be thoroughly 
tested to guarantee the efficacy of attenuation). For these rea-
sons, modern vaccines are often based on chemically defined 
recombinant proteins, which are much easier to manufacture. 
Nevertheless, for these proteins to work efficiently as vaccines, 
they must be in a conformation that will elicit the generation of 
host antibodies that recognise antigens natively expressed on the 
surface of the parasite. Although popular heterologous 
expression systems such as bacteria and yeast have been 
successfully used for the generation of intracellular proteins, 
they are not generally regarded as suitable for the systematic 
production of secreted and cell-surface proteins, which require 
the formation of disulphide bonds for their correct folding and 
the addition of glycan structures. Also, the differences in 
adjuvants, routes of delivery, immunisation regimes and heter-
ologous expression systems used to produce the antigens can 
lead to contradictory results on the protective effect of certain 
antigens25–27. We have recently described a library of secreted 
and cell-surface S. mansoni proteins whose selection was based 
on published proteomics studies and transcriptional data at the 
schistosomula stage28. Importantly, these proteins were expressed 
in human embryonic kidney (HEK)-293 cells, to increase the 
chances of forming disulphide bonds that are critical for the 
correct tertiary folding of extracellular proteins. Testing against 
sera from patients living in a high-endemicity area showed that 
most of them contain heat-labile conformational epitopes28.
In this study, we have produced and purified 96 antigens 
from this library for immunisation in mice. By establishing 
infrastructures for large-scale systematic challenges and stand-
ardised infection parameters, we have systematically tested the 
protective efficacy of these antigens in immunised mice against 
infection with S. mansoni cercariae.
Methods
Expression and purification of recombinant antigens from 
mammalian HEK-293-E cells
Antigens (Table 1) were produced by transient transfection 
of human embryonic kidney (HEK)-293-E or HEK-293-6E 
cells (provided by Yves Durocher, NRC, Montreal); cells were 
regularly tested for mycoplasma (every six months) by Surrey 
Diagnostics, UK. Expression plasmids containing an exog-
enous signal peptide of murine origin, the complete extracellular 
domain of the protein of interest, a recognition sequence for 
enzymatic biotinylation by the BirA biotin ligase and a 6-His 
tag were transiently transfected into HEK cells as previously 
described29,30. Where expression of the recombinant protein 
could not be achieved, a rat Cd4d3+4 tag was inserted in the 
expression construct between the sequence encoding the 
ectodomain of interest and the biotinylation sequence, which can 
facilitate expression and secretion of the recombinant protein31. 
At 6 days after transfection, cell culture supernatants were 
collected, filtered and supplemented with 20 mM imidazole 
and 400 mM NaCl before being affinity-purified on HisTrap HP 
purification columns (GE Healthcare) using an AKTAPure 
instrument, according to the manufacturer’s instructions. The 
purified protein fractions were dialysed in phosphate-buffered 
saline (PBS) and quantified by optical density measurement at 
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Table 1. Immunisation of BALB/C female mice with 96 recombinant Schistosoma mansoni proteins produced 
in mammalian cells. The protein number, accession number, molecular mass (MM) in kiloDaltons, presence of 
a rat Cd4d3+4 tag on the antigen, antigen doses and half-maximal serum antibody titres are indicated. Rows 
shaded in grey correspond to proteins that could not be produced or could not be purified in sufficient amounts 
for immunisations. Where proteins were produced without and with a Cd4 tag, the molecular mass of the untagged 
form is indicated first.
Number UniProt accession number MM Cd4 tag Antigen dose Half-maximal titre (1:x)
Cell surface
1 Smp_195190 13 - 100-20-20 8,851
2 Smp_081920 21 - 100-20-20 10,023
3 Smp_166340 24 - 100-20-20 147,432
4 Smp_017730 233 - 100-20-20 331,183
5 Smp_127820 108 - 100-20-20 447,516
6 Smp_194920 70 - 100-20-20 499,904
7 Smp_011680 -
8 Smp_054070 40 - 100-20-20 1,257,140
9 Smp_073400 45 - 100-20-20 73,944
10 Smp_105220 16 - 100-20-20 188,373/48,073 (repeat)
11 Smp_019350 8/38 -/+ 100-20-20 397(-)/38,066 (+)
12 Smp_021220 30 - 100-20-20 34,117
13 Smp_031880 35 - 100-20-20 507,714
14 Smp_009830 48 + 45-20-20 8,717
15 Smp_032520 40 - 100-20-20 233,184
16 Smp_074000 56 + 100-20-20 41,910
17 Smp_102480 14/37 -/+ 100-20-20 39(-)/71,705(+)
18 Smp_124000 15/38 -/+ 100-20-20 62(-)/15,405(+)
19 Smp_156270 48 + 100-20-20 125,921
20 Smp_174580 35 - 100-20-20 1,017,180
21 Smp_176020 10/34 -/+ 100-20-20 (-)/75-20-20 (+) 0(-)/1,284(+)
22 Smp_048380 73 + 100-20-20 374,183
23 Smp_060570 85 + 100-20-20 11,048
24 Smp_075280 45 - 100-20-20 122,414
25 Smp_129840 183 - 100-20-20 350,096
26 Smp_133270
27 Smp_145420
28 Smp_149740 97 - 100-20-20 239,927
29 Smp_155810 160 - 100-20-20 69,118
30 Smp_162520 162 + 30-20-20 0
31 Smp_164760 160 - 50-20-20 195,225
32 Smp_166300 70 - 100-20-20 161,156
33 Smp_168240 45 - 100-20-20 332,665
34 Smp_171460 138 - 80-20-20 181,682
35 Smp_176540 123 - 100-20-20 165,471
36 Smp_157070 80 + 100-20-20 82,856
37 Smp_165440 51 - 100-20-20 61,012
38 Smp_136690 75 - 100-20-20 378,652
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Number UniProt accession number MM Cd4 tag Antigen dose Half-maximal titre (1:x)
Cell surface
39 Smp_061970
40 Smp_153390 71 - 100-20-20 1,379,630
41 Smp_072190 37 - 100-20-20 277,781
42 Smp_064430 24 - 100-20-20 201,941
Secreted adhesion/growth factor/metabolite binding
43 Smp_194840 24 - 100-20-20 1,048,470
44 Smp_194910 28 - 100-20-20 329,926
45 Smp_063530 26 - 100-20-20 49,886
46 Smp_141680 87 - 90-20-20 535,508
47 Smp_043650 37 + 100-20-20 84,269
48 Smp_170550 140 - 100-20-20 379,757




53 Smp_136320 24 - 100-20-20 72,442
54 Smp_144130 118 + 100-20-20 129,754
55 Smp_154760 274 - 100-20-20 356,003
56 Smp_171780 37 - 100-20-20 158,384
57 Smp_178740
58 Smp_180600 48 - 100-20-20 489,748/347,980 
(repeat)
59 Smp_181220 27 - 100-20-20 20,622
60 Smp_211020
61 Smp_016490 29 - 100-20-20 52,662
62 Smp_130100
63 Smp_105420 30 - 100-20-20 265,183
64 Smp_105450 34 - 100-20-20 14,672
65 Smp_202610 23 - 100-20-20 109,506
Secreted protease/protease inhibitor
66 Smp_090100 104 + 20-10-10 2,243
67 Smp_067060 48 - 100-20-20 198,630
68 Smp_103610 49 - 50-20-20 14,029
69 Smp_019030 68 - 80-20-20 117,774
70 Smp_002600 111 + 80-20-20 0
71 Smp_071610 75 - 100-20-20 498,134
72 Smp_089670 386 - 100-20-20 97,493
73 Smp_112090
74 Smp_119130
75 Smp_002150 97 + 20-10-10 19,799
76 Smp_141610 49 - 100-20-20 57,720
77 Smp_147730 24/47 -/+ 100-20-20 1,008(-)/9470(+)
78 Smp_034420 33 - 100-20-20 68,400
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Number UniProt accession number MM Cd4 tag Antigen dose Half-maximal titre (1:x)
Secreted protease/protease inhibitor
79 Smp_075800 59 - 100-20-20 268,007
80 Smp_210500 52 - 100-20-20 478,317
81 Smp_132480 56/79 -/+ 60-20-20(-)/55-20-20(+) 31,288(-)/0(+)
82 Smp_166280 55 - 100-20-20 423,594
83 Smp_187140 50 - 20-10-10 0
84 Smp_006510
85 Smp_090110
Secreted enzyme (not protease)
86 Smp_145920 71 + 80-20-20 0
87 Smp_040790 30 - 100-20-20 303,955
88 Smp_008320
89 Smp_021730 52 + 100-20-20 18,946
90 Smp_078800 49 + 100-20-20 86,998
91 Smp_007450 25 - 80-20-20 86,888
92 Smp_026930 55 - 100-20-20 311,900
93 Smp_059910
94 Smp_089240
95 Smp_134800 243 + 40-20-20 25,828
96 Smp_018760 129 - 100-20-20 59,257
Secreted venom/secreted MEGs/short
97 Smp_194860 39 + 50-20-20 6,595
98 Smp_138080 30 - 100-20-20 44,679
99 Smp_194830 13/37 -/+ 100-20-20 1,964(-)/36,345(+)
100 Smp_001890 32 - 100-20-20 121,269
101 Smp_002070 34 - 100-20-20 202,207
102 Smp_138060 23 - 100-20-20 18,384
103 Smp_180620 18/41 -/+ 100-20-20 0(-)/25,592(+)
104 Smp_123540 37/57 -/+ 60-20-20 (- and +) 276,631(-)/292,600(+)
105 Smp_123550 42 - 100-20-20 247,541
Secreted - no known function
106 Smp_181070 43 + 20-20-20 54,950
107 Smp_004710 42 + 100-20-20 43,386
108 Smp_061310
109 Smp_005060
110 Smp_141500 56 + 100-20-20 47,639
111 Smp_006060 69 - 100-20-20 338,372
112 Smp_063330 25 - 100-20-20 237,942
113 Smp_096790 38 + 100-20-20 38,574
114 Smp_201730 38 + 100-20-20 74,319
115 Smp_019000 29/53 -/+ 100-20-20 0(-)/1,135(+)
-/+: antigens without the Cd4 tag that did not raise high levels of antibodies were produced a second time as Cd4-tagged proteins 
and immunised in a separate group of animals. For most antigens, mice were first immunised with 100 µg antigen followed by two 
fortnightly injections of 20 µg protein (100-20-20). Where amounts of purified antigens were not sufficient to follow this dosage, 
lower amounts of antigens were used as indicated in the table. (-) or (+) indicates results obtained in the absence or presence of a 
Cd4 tag on the antigen, respectively. In cases of proteins 10 and 58, antibody titres where immunisations were repeated on larger 
cohorts of animals are indicated (repeat).
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280 nm. To check for purity and integrity of the purified 
proteins, a 2-µg sample was resolved by SDS-PAGE on 
NuPAGE 4–12% Bis-Tris polyacrylamide gels (ThermoFisher) 
for 50 minutes at 200 V. The gels were then stained with SYPRO 
Orange (ThermoFisher), destained in 7.5% acetic acid and 
imaged using a Typhoon 9400 phosphoimager (GE Healthcare). 
The remainder of each purified protein was aliquoted and stored 
at -20°C until the day of immunisation. These gels are shown in 
Underlying data32.
To prepare biotinylated antigens for determination of antibody 
titres, the BirA biotin ligase was co-transfected at the same time 
as the expression constructs described above into HEK-293-E or 
-6E cells as previously described33. Supernatants were collected 
six days post-transfection, dialysed in HEPES-buffered saline, 
and their level of expression determined by ELISA as previously 
described29.
Maintenance of the S. mansoni parasite life cycle and 
preparation of cercariae
All animal experiments were performed in accordance with UK 
Home Office regulations under project licenses P77E8A062 and 
PD3DA8D1F, and following approval from the local Animal 
Welfare and Ethical Review Body. The life cycle of the NMRI 
(Puerto Rican) strain of Schistosoma mansoni was maintained 
by routine infections of BALB/C female mice and Biomphalaria 
glabrata snails. Infected snails were housed in aerated tanks 
kept in dark cupboards maintained at 28°C. For collection of 
cercariae, 20 to 50 infected snails were individually washed 
in conditioned water, pooled in a small glass beaker, sub-
merged in conditioned water and exposed to bright light34. After 
60 minutes, the conditioned water containing live cercariae was 
collected. To evaluate the concentration of cercariae in solution, 
12 5-µL aliquots were sampled, mixed with Lugol (Sigma 
Aldrich), and cercariae contained in each individual drop 
were counted under a dissecting microscope. For infection 
challenges, the cercarial solution was subsequently diluted in 
conditioned water to a final concentration of 400 cercariae/mL, 
and immediately used for percutaneous infection.
Immunisation and percutaneous infection of BALB/C mice
Mice were obtained from the Research Support Facility, 
Sanger Institute and typically had a mass of 25 g. Mice were 
housed in GM500 Individually Ventilated Cages or IsoCage N - 
Biocontainment Systems (Tecniplast) and maintained on 
individual air handling units kept at between 19 to 23°C and 
45–65% humidity; each cage received 60 air volume changes 
per hour. Mice were given access to food and water ad libitum 
and maintained on a 12-hour light/dark cycle. Aspen wood chip 
was used as the base bedding with nestlets and “fun tunnels” for 
environmental enrichment (Datesand). Mice were housed in 
groups of no more than 6 adults per cage. Welfare assessments 
were carried out daily as part of the morning check. This involved 
moving the cage forward on the rack runners and observing 
the mice in their micro-environment. Any abnormal signs of 
behaviour or physical clinical signs of concern were reported. 
“In hand” weekly health assessments were also performed, and 
every cage was removed from the rack and each mouse given a 
full “head to toe” health check. All persons performing welfare 
checks on animals were trained and assessed as competent by 
qualified individuals.
For each antigen studied and on the day of immunisation, aliquots 
of purified protein were thawed, diluted in PBS and mixed 
50% v/v with Alhydrogel adjuvant 2% (InvivoGen) for 2 hours 
at room temperature. For each antigen, a group of five 7-week 
old female BALB/C mice was immunised intraperitoneally 
initially with 100 µg protein followed by two additional 
fortnightly immunisations using 20 µg protein. Where the 
quantity of purified antigen was insufficient to achieve these 
levels, lower doses of proteins were administered, as described 
in Table 1. In each group, a sixth animal was injected with 
PBS mixed 50% v/v with Alhydrogel 2% and used as a cage 
control.
After a 4-week rest period, animals were challenged with 200 
S. mansoni cercariae for 40 minutes by percutaneous infection 
through the tail. For this purpose, test tubes containing 5.5 mL 
conditioned water were prefilled and placed onto a bespoke 
anaesthesia rig (see below) pre-warmed to a surface tempera-
ture of 32°C. Mice were anaesthetised in an induction box using 
4% isoflurane; 1 L/min oxygen, and an eye ointment was used 
to prevent corneal damage. After induction of anaesthesia, the 
animals’ tails were wiped with a tissue soaked with condi-
tioned water to remove any contaminants from the cage bedding 
that could inhibit cercarial penetration, immersed once more 
in conditioned water before carefully transferring the animals 
onto individual holders on the rigs and inserting their tails into 
the test tubes. Nose cone positions were adjusted for each animal, 
and anaesthesia was maintained at 2% isoflurane; 1L/min 
oxygen. Individual splash guards were put in place to reduce 
the possibility of human exposure to infected water. In each test 
tube, 500 µL of a stock solution containing 400 cercariae/mL 
was added. After 40 minutes, animals were removed from the 
anaesthesia rigs, placed back into their cage and monitored 
until full recovery from the anaesthesia. At 42 days after the 
challenge, mice were euthanised by intraperitoneal injection 
of 200 µL of 200 mg/mL pentobarbital supplemented with 
100 U/mL heparin; adult worms were recovered after portal 
vein section and intracardiac perfusion with phenol-red-free 
DMEM supplemented with 10 U/mL heparin, and whole livers 
were collected. Worms collected from individual mice were 
washed three times in PBS and placed in 6-well plates for 
counting. Liver tissues were weighed and then digested by 
incubation in 10 mL of 4% potassium hydroxide for 15 hours 
at 37°C36. The number of eggs per gram of liver was calculated 
after counting the number of eggs from 12 10-µL aliquots from 
each liver homogenate.
Determination of antibody titres by ELISA
At 8 days after the last immunisation, blood samples (20 to 
50 µL) were collected by tail bleed from each animal and left to 
clot for two hours at room temperature. After centrifugation, 
sera were collected and stored at -20°C after addition of 2 mM 
sodium azide. To determine the antibody titre against an antigen 
of interest, individual sera were serially diluted 1:4 between a 
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1:2,000 and a 1:8,192,000 dilutions in HBST/2% BSA. Depend-
ing on the presence or absence of a Cd4 tag in the antigen 
studied, these serial dilutions were pre-incubated overnight 
at room temperature with 1 mg/mL or 100 µg/mL of the rat 
Cd4d3+4-BLH protein, respectively, to block the fraction of 
antibodies that were raised against the tag in immunised 
animals. Serially diluted sera were then transferred to strepta-
vidin-coated ELISA plates on which the biotinylated 
antigen of interest had been immobilised. To ensure that the 
antibody fraction directed against the protein tag had been 
blocked, binding of the lowest dilution of antisera was also 
tested against the control rat Cd4d3+4-BLH protein immobi-
lised on an ELISA plate to confirm absence of anti-tag reactivity. 
Detection was performed using an alkaline-phosphatase 
anti-mouse immunoglobulin secondary antibody followed by 
incubation with an alkaline phosphatase substrate, as previously 
described29.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 
(version 5) software. Data from serum analysis were analysed 
using a non-linear regression model to determine half-maximal 
antibody titres. R2 scores between the number of eggs per gram 
of liver and the total number of adults or the total number of 
mature females were calculated by linear regression analysis. 
Comparison of average numbers of eggs per gram of liver 
between groups of immunised animals in a same cohort was 
performed using one-way ANOVA analysis followed by 
Bonferroni correction. Where immunisations were repeated 
on larger cohorts of animals, an unpaired t-test was used to 
compare average numbers of eggs in immunised and control 
animals; P-values ≤ 0.05 were considered to be significant.
Results
Optimising the conditions for percutaneous infections by 
S. mansoni in mice
To compare the protective efficacy of a large number of anti-
gens in a systematic manner, we first decided to optimise the 
experimental conditions of S. mansoni infection in mice. These 
are usually done either by intra-peritoneal injection of cer-
cariae or by exposure of the skin to the parasite (percutaneous 
infection)34. Because a large fraction of the antigens to be 
tested correspond to parasite proteins expressed in the early 
dermal stages of infection, we opted to use the percutaneous 
method, which is also a natural route of infection. This 
protocol, however, requires a relatively lengthy exposure of 
either restrained or anaesthetised animals to infested water. 
To minimise unnecessary stress to the animal and biological 
safety risks to the experimentalist, we designed a bespoke 
anaesthesia apparatus that allowed for prolonged exposure to 
the parasite by tail immersion into cercariae-containing water 
while animals were under the influence of a gaseous anaesthetic 
(Figure 1A). The instruments were fitted with an inlet 
connected to a vaporiser for delivery of anaesthetics, and an 
outlet linked to a scavenging system for disposal of waste gases. 
Each device could accommodate up to six animals and was 
divided into six individual compartments, each with its own 
holder, splash guard, adjustable nose cone and test tube holder 
for immersion of the animals’ tails into cercariae-containing 
water. To ensure animals did not suffer from hypothermia 
during anaesthesia, the instruments were fitted with heat-pads, 
a heat controller and temperature sensors and the surface 
temperature maintained to 32°C throughout the experiment. 
All of the infection challenges described in this study were 
performed using these devices.
As mouse infection by Schistosoma parasites can be affected 
by the presence of testosterone36, we decided to use female 
mice of the BALB/C strain, which have a robust Th2-type 
immune response37. To determine the optimal duration of the 
infection challenge, two groups of animals were infected with 
the same preparation of cercariae for either 20 or 40 minutes and 
their infection levels measured six weeks later by counting the 
number of eggs per gram of liver. Although all challenged 
animals were infected, the inter-individual variability was smaller 
in the group exposed for 40 minutes (Figure 1B). Increasing 
the infective dose to 300 or 400 cercariae for 40 minutes led 
to an increase in premature mortality around three weeks 
post-infection (two out of six mice had to be euthanised 
prematurely in the group challenged with 300 cercariae; and 
five out of five in the group challenged with 400 cercariae). 
Based on these observations, infection challenges were stand-
ardly performed by immersing the tail of anaesthetised mice in 
6 mL of conditioned water containing 200 S. mansoni cercariae 
for 40 minutes.
To elicit high levels of antibodies against specific antigens, 
we opted to use Alhydrogel, a relatively mild alum-based 
human-compatible adjuvant, which promotes a Th2-type host 
response38. In some vaccine experiments, administration of 
adjuvant alone can also confer some protective effect, possi-
bly through the general stimulation of the host immune sys-
tem. To determine whether Alhydrogel could cause a so-called 
“adjuvant effect”, we immunised three groups of animals 
three times fortnightly with a control protein in 1% Alhy-
drogel before challenging them two, four or six weeks 
post-immunisation. No statistically significant difference in the 
average infection levels could be observed between the three 
groups of animals, although the inter-individual variability was 
greater in the group challenged two weeks after the final boost 
(Figure 1C). Based on these observations and to reduce the lead 
time of each experiment, we decided to adopt a 4-week rest 
period between the final immunisation and the infection 
challenge. Raw data for optimisation of immunisation and rest 
periods are available as Underlying data32.
Cell-surface and secreted S. mansoni antigens generate a 
strong host immune response
We have recently described the selection of a panel of 
S. mansoni cell-surface and secreted proteins identified from 
proteomics and transcriptional studies, of which 103 could 
be produced recombinantly in human embryonic kidney 
(HEK)-293 cells as soluble ectodomains containing a C-terminal 
rat Cd4d3+4 tag followed by a sequence for enzymatic 
monobiotinylation and a 6-His tag for purification28. The major-
ity of these proteins were immunoreactive when tested against 
sera from S. mansoni-infected patients living in areas of high 
endemicity, and contained heat-labile epitopes demonstrating the 
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Figure 1. Anaesthesia rig for percutaneous infection of mice with Schistosoma parasites and challenge optimisation. (A) Each 
anaesthesia rig is divided into six individual compartments, each with their own adjustable nose-cone, splash guard and animal holder 
(yellow) for the safe removal of animals after the challenge. Test tubes (red), containing cercariae-infected water, are placed onto a removable 
tube holder (blue). Surface temperature of the instrument is maintained at 32°C using heat pads located underneath each compartment and 
controlled by a heat controller and temperature sensors (not shown on the figure). (B) 12-week-old BALB/C female mice were challenged 
with 200 S. mansoni cercariae from the same parasite preparation for either 20 minutes (n = 5 animals) or 40 minutes (n = 5). The numbers 
of eggs per gram of liver were counted 42 days later from whole liver preparations from each animal. Inter-individual variability was greater 
between animals that had been challenged for 20 minutes compared to those challenged for 40 minutes. (C) Three groups of 6-week-old 
BALB/C female mice were immunised three times fortnightly with 100 µg of a control protein in 1% Alhydrogel. The first group (n = 6 animals) 
went through a 2-week rest period between their final immunisation and the infection challenge with 200 S. mansoni cercariae, while the 
second group (n = 6) had a 4-week rest period and the third group (n = 6) had a 6-week rest period. The numbers of eggs per gram of liver 
were counted 42 days later from whole liver preparations from each animal. No statistically significant difference in the average number of 
eggs could be identified between the three groups of animals. Note that the group of animals with a four-week rest period was infected with 
a different cercarial preparation from the other two groups.
presence of conformational epitopes. We attempted to produce 
all 103 antigens as soluble 6-His-tagged proteins (without the 
C-terminal rat Cd4 tag) and managed to obtain 74 antigens in 
quantities sufficient to perform immunisations in mice. For another 
22 antigens, sufficient expression levels could only be achieved 
when these proteins were produced as C-terminally Cd4-tagged 
and 6-His-tagged antigens. Finally, seven proteins (Proteins 
7, 51, 52, 57, 62, 88 and 108) were not expressed at sufficient 
levels to perform immunisations in either form (Table 1). All 
96 proteins were purified by Ni2+ affinity-purification and the 
integrity of all purified proteins was determined on protein gels 
(Figure 2); these included very large proteins such as protein 
55 (274 kDa) or protein 72 (386 kDa). Given the large number 
of antigens to be tested and because we were attempting to 
identify protective candidates conferring a large effect size, we 
performed the immunisations and challenges in cohorts, each 
comprising of three groups of one control and five experimen-
tal animals, where each group was vaccinated with a different 
protein. For all but 18 antigens, sufficient amounts of protein 
were produced to immunise the mice with one initial injection 
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Figure 2. The 96 recombinant cell-surface or secreted Schistosoma mansoni antigens produced in mammalian HEK-293E cells. 
Proteins were purified by Ni2+-affinity purification using their carboxy-terminal 6-His tag and a small aliquot (2 µg) resolved by SDS-PAGE. 
Numbering of the proteins corresponds to Table 1. The suffix C indicates antigens that were produced with an additional rat Cd4d3+4 tag at 
their C-terminal end. Proteins were typically heterogeneous in mass, reflecting the presence of different glycoforms in the preparation. In the 
case of low-expressing proteins, contaminants originating from the cell culture supernatant occasionally co-purified alongside the protein of 
interest and appear as fainter background bands on the gels. Molecular masses (kDa) are indicated on the left-hand side of each composite 
picture. Adjustments to brightness and contrast for individual proteins were performed using the Adobe Photoshop CS5 software to improve 
clarity.
of 100 µg protein per animal followed by two subsequent 20-µg 
boosts. Where protein expression was not sufficient to achieve 
this regime, lower doses of antigens were administered as 
described in Table 1. At 8 days after their final immunisation, 
blood samples were taken from each animal and the antibody 
titres determined by ELISA (Figure 3A). We arbitrarily 
decided that average half-maximal antibody titres >1:10,000 
constituted “good” immune responses from the groups of 
animals tested, while titres <1:2,000 were considered as “insuf-
ficient”. Eight proteins produced without a Cd4d3+4 tag raised 
insufficient immune responses, resulting in average half- 
maximal titres lower than our arbitrary cut-off of 1:2,000 
(Proteins 11, 17, 18, 21, 77, 99, 103 and 115). In these instances, 
the same proteins were produced again in their Cd4-tagged 
form, and immunisations were repeated on different groups of 
animals. This approach generally improved the antigenicity 
of the ectodomains of interest: in five out of eight cases, 
reactivity to the recombinant parasite ectodomains resulted 
in average half-maximal titres greater than 1:10,000. Overall, 
most recombinant parasite proteins proved to be antigenic with 
all but 11 antigens giving half-maximal titres greater than 
1:10,000 (89%, Table 1, Figure 3B). Of the 11 antigens with lower 
reactivity, four produced no immune response (Proteins 30C, 
70C, 83 and 86C). Antibody titres are available as Underlying 
data32.
A systematic challenge of immunised animals with 
S. mansoni does not identify strongly protective antigens
To determine whether any of the antigens tested had a 
protective effect against infection by Schistosoma mansoni, 
each group of immunised animals was challenged four weeks 
after their final immunisation with 200 cercariae for 40 minutes. 
Because preparations of cercariae differed in their infective 
efficiency, each batch of parasite was used to simultaneously 
challenge cohorts of three groups of animals, each immunised 
with a different protein. In total, 36 cohorts were challenged 
to test the protective efficacy of 96 recombinant S. mansoni 
proteins.
At 42 days after infection, the animals were euthanised, 
perfused, and their livers were collected. Two parameters were 
measured to determine the levels of infection: the total number 
of worms recovered after perfusion, and the number of eggs 
per gram of liver. In one cohort, the infection challenge failed 
as even the PBS-immunised control animals from each cage 
in this cohort showed no sign of infection, and mice immunised 
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Figure 3. Recombinant cell-surface and secreted Schistosoma mansoni antigens raised robust immune responses in mice. 
(A) Experimental timeline detailing the immunisation regime, blood sampling, percutaneous infection and sample collection followed for 
each group of immunised animals. (B) The average half-maximal antibody titres of mice immunised with individual antigens are shown. The 
suffix C indicates the presence of a C-terminal rat Cd4d3+4 tag in the antigen tested. Protein numbering corresponds to that presented 
in Table 1. Antigens that were initially tested without a Cd4 tag and induced half-maximal titres <1:10,000 are shown as grey circles. Four 
antigens (proteins 30C, 70C, 83 and 86C) did not induce any humoral response and are indicated by grey stars. Datapoints represent 
mean ± SD; n = 5 or more animals per group, with the exception of proteins 13, 18C, 28 and 42 (n = 4), and protein 17C (n = 3) due to 
premature mortality.
Figure 4. The number of eggs per gram of liver correlates with the number of adult worms. (A) For each group of immunised animals, the 
average number of eggs per gram of liver was plotted against the average number of S. mansoni worms per animal recovered after perfusion. 
A high correlation (R2 = 0.80) was observed between the two measurements. Red arrows indicate groups of animals immunised with proteins 
98 and 100, in which a marked deficit in the number of eggs compared to the total number of adult worms was observed. This was attributed 
to a sex ratio imbalance in the cercarial preparation used for the infection challenge, resulting in an excess of (mostly sexually immature) 
female worms. Across all groups of animals tested, variability in parasite recovery ranged from 6 to 64%, reflecting the heterogeneity in the 
cercarial preparations used to infect the different cohorts of animals. (B) For each group of immunised animals, the average number of eggs 
per gram of liver was plotted against the average number of mature female worms per animal recovered after perfusion. A high correlation 
was observed between both measurements (R2 = 0.88).
with proteins 14C and 23C were therefore excluded from the 
study. Overall, we observed a good correlation between the 
number of adult worms and the number of eggs per gram of 
liver (R2= 0.80; Figure 4A) across all groups of immunised 
animals tested, and this correlation improved further if 
only morphologically mature adult females were taken into 
consideration (R2= 0.88; Figure 4B). However, we observed 
significant variability in infection efficacy between the batches of 
cercariae used: the percentage of parasite recovery ranged from 
6 to 64% (Figure 4A) and on average, the percentage recovery 
of adult worms across all groups studied was 25%. In the few 
cases where a marked deficit in the number of eggs was observed 
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when compared to the total number of adult worms (proteins 
98 and 100, Figure 4A), we noticed a similar phenomenon in 
the control animals from this cohort. This was attributed to a 
strong sex ratio imbalance in the cercarial preparation used to 
challenge the cohort, resulting in a vast excess of immature 
females.
Given the good overall correlation between the average number 
of worms recovered after perfusion and the average number of 
eggs per gram of liver observed in the groups studied, we 
based our next analysis on the number of eggs per gram of 
liver recovered after whole liver digestion. This also presented 
with the added advantage of measuring the level of infection 
as well as any effect an antigen could have on female worm 
fecundity. A summary of all cohorts studied is presented in 
Figure 5A. To identify statistically significant differences 
between groups of animals within the same cohort - which were 
all infected with the same batch of cercariae - the numbers of 
eggs per gram of liver from each of the three groups of 
immunised animals were compared to each other by ANOVA 
analysis and Bonferroni correction. Using this approach, 
animals immunised with proteins 10 (Smp_105220) and 58 
(Smp_180600) showed a statistically significant reduction 
by ANOVA analysis (p=0.0029 and p<0.0001, respectively) 
when compared to the other two groups from their respective 
cohorts (Figure 5B), while those immunised with proteins 72 
(Smp_089670) and 90C (Smp_078800) showed a statistically 
significant reduction (p<0.05) compared to one group from their 
cohort.
To confirm these observations, we repeated the immunisations 
for proteins 10 and 58 on a larger number of animals. Three 
cages each containing four animals immunised with the protein 
of interest (n = 12) and two PBS-immunised controls (n = 6) 
were compared. In both repeats, the average half-maximal 
antibody titres were lower than in the primary screen at 1:48,073 
for protein 10 and 1:347,980 for protein 58. We did not see any 
statistical difference between control animals and those 
immunised with protein 58 in this larger cohort. With the 
exception of one control animal, which only had a few mature 
females and therefore had a much lower egg burden, we once 
again observed a trend towards a reduced number of eggs per 
gram of liver in animals immunised with protein 10 compared to 
controls, although this observation did not reach statistical 
significance (Figure 5C). All values concerning egg counts are 
available as Underlying data32.
Figure 5. Systematic challenge of animals immunised with Schistosoma mansoni antigens does not identify strongly protective 
candidates. (A) An overview of the 36 cohorts of immunised animals challenged with S. mansoni cercariae. Each cohort is represented by a 
different colour and is composed of two or three groups of animals. For each group of immunised animals, the average number of eggs per 
gram of liver has been normalised to the average number of eggs per gram of liver of the PBS-immunised controls from the same cohort. 
Red or blue arrows indicate groups of animals that showed statistically significant difference from two or one group of the same cohort, 
respectively. Datapoints are mean ± SD; n = 5 or more animals per group, with the exception of proteins 17, 18C, 28, 40, 55, 56, 64, 66C, 69, 
81, 87, 99C and 102 (n = 4), and proteins 13, 17C and 42 (n = 3) due to premature mortality. (B) Details of individual datapoints in cohorts 
corresponding to antigens 10 and 58, for which a statistically significant difference in the number of eggs per gram of liver was observed 
by ANOVA analysis compared to the other groups from the same cohort (p=0.0029 and p<0.0001, respectively). Bars are mean ± SD; 
n = 5 animals per group, with the exception of protein 13 due to premature mortality. (C) Repeat experiments with antigens 10 and 58 on larger 
cohorts of animals shows no statistically significant difference between animals immunised with the antigen of interest (n = 12) compared to 
animals who received PBS (n = 6). Individual datapoints are shown. Bars are mean ± SD.
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Discussion
Schistosomiasis is a debilitating parasitic disease that plagues 
the lives of millions of individuals across the globe. With 10% 
of the world population living in areas where schistosomiasis is 
endemic and more than 70 million people needing treatment 
every year, the development of new preventative methods 
remains a priority. Mass administration of praziquantel to 
populations at risk of contracting the disease is, however, the 
most common method of prevention and treatment in human 
populations, and very few vaccine candidates have progressed 
to clinical trials so far. In this study, we have systematically 
compared the protective efficacy of 96 cell-surface and secreted 
antigens from S. mansoni produced in a mammalian expres-
sion system. This is, to our knowledge, the largest set of 
Schistosoma proteins tested in parallel in protection experiments 
to date.
By using a mammalian expression system, we have sought to 
improve the tertiary conformation of the recombinant antigens 
tested, in particular the formation of structurally critical disulphide 
bonds. Indeed, immunoreactivity experiments on these proteins 
against patients’ sera from a highly endemic area have shown that 
the vast majority of them contain heat-labile conformational 
epitopes28, which are indicative of their correct folding.
Throughout the study, we have adopted very systematic 
protocols for antigen production, immunisation and infection 
challenges to limit experimental variability. For example, 
recombinant proteins were systematically produced in HEK-293 
cells and the quality of the purified antigens assessed by 
SDS-PAGE; strict timings were observed between immunisa-
tions (every two weeks) and between the last immunisation 
and the infection challenge (four weeks); all cercarial prepara-
tions were carefully counted and used within one hour of cercarial 
shedding for infection; the tails of all animals were carefully 
wiped and immersed in conditioned water before the infection 
to avoid any inhibitory effect of residual oils present in animal 
bedding on parasite penetration. Despite these precautions, 
we still observed significant variability in the efficiency of 
infection and, in some cases, sex ratio imbalance in the 
cercarial preparation, which resulted in an excessive number 
of adult worms compared to the number of eggs produced. One 
way to better control this imbalance would be to use snails singly 
infected with male or female miracidia and mix the cercariae 
produced by these snails in equal quantities.
Of the 96 recombinant candidates that were tested, all but 11 
were antigenic enough to generate half-maximal titres 
> 1:10,000 (our arbitrary criterion for a good humoral response), 
and only four did not raise any immune response. The lower 
immunogenicity of some proteins could be attributed to their 
relatively small sizes (six of them had a molecular mass 
<50 kDa) or to the lower antigen doses administered during 
immunisations because of poor expression. Despite overall high 
reactivities, we could not observe any reproducible protective 
effect from antibodies raised against the antigens tested. These 
include proteins that had previously been proposed as vaccine 
candidates such as Sm2939 or cathepsin B40. Other promising 
vaccine candidates such as the intracellular protein Sm-p8041 
or the multimembrane spanning SmTSP226 were not included in 
our screen since their subcellular localisation or structure were 
not compatible with secretion of the recombinant proteins by 
HEK-293 cells in the culture supernatant. One possible 
explanation for the lack of protective efficacy observed in our 
study could be a biased immune response caused by the adjuvant 
that we used for immunisations. When designing this system-
atic study, we selected an adjuvant that could induce a good 
humoral response in mice but could also be transferable to 
human vaccine studies. Alhydrogel is a mild aluminium-
hydroxide-based adjuvant commonly used in human vaccine 
formulations, which induces a Th2-type immune response 
mostly skewed towards the production of IgG1 antibodies42,43. 
While this antibody isotype results in high-affinity neu-
tralising antibodies in mouse, it is far less efficient in 
recruiting complement and binding to activating Fcγ receptors44. 
The use of alternative adjuvants associated with a more 
balanced Th1/Th2 immune response such as Quil A might 
therefore be considered. One alternative explanation could be 
functional redundancy between some of the proteins tested. 
Our protein library contains multiple members of large 
protein families (Ly6, MEG, saposins, cathepsins, VAL, etc) 
and although these members are immunologically distinct, they 
could be functionally redundant. Immunisation with mixtures of 
antigens from the same family of proteins could therefore also be 
considered.
Of all the candidates that we tested, proteins 10 and 58 showed 
a statistically significant decrease in the number of eggs per 
gram of liver in the primary screen when compared to the 
other two immunised groups from their respective cohort. 
However, only protein 10 showed a similar trend in the repeat 
experiment on a larger number of animals, although this did not 
reach statistical significance. This protein belongs to the Ly6 
family of proteins and is also known as SmLy6B/SmCd59b. 
In previous studies, SmLy6B has been shown to be widely 
expressed in both male and female worms45 and mice immu-
nised with a DNA vaccine encoding the corresponding gene 
showed a reduced worm burden close to statistical significance15. 
Interestingly, the proportion of mature adult females recovered 
after perfusion in our experiment was similar between immunised 
and control groups (46.4% adult females in immunised animals 
versus 45.3% mature females in controls), while the average total 
number of worms recovered was slightly smaller in the group 
vaccinated with protein 10 (27 worms versus 33 worms in the 
PBS controls). Individual cohort data for antigens 10 and 58, in 
addition to repeat analysis on larger groups, are available as 
Underlying data32.
In conclusion, we have developed a technical infrastructure to 
refine the conditions of percutaneous infection in mice and to 
systematically screen a large number of recombinant cell-surface 
and secreted antigens from S. mansoni as vaccine candidates. 
Although the vast majority of the 96 proteins tested raised a 
robust immune response in mice, none of them were associ-
ated with a strong protective effect against infection by the par-
asite and the identification of new vaccine candidates against 
schistosomiasis remains much needed. We hope nonetheless that 
these antigens will constitute a useful resource for the scientific 
Page 13 of 21
Wellcome Open Research 2019, 4:159 Last updated: 25 MAY 2020
community and that their role as vaccine candidates will be further 
explored in the context of different adjuvants, as components of 
protein mixtures or in other animal models.
Data availability
Figshare: Data files describing the systemic screening of 96 
Schistosoma mansoni cell surface and secreted antigens 
produced in a mammalian expression system. https://doi.
org/10.6084/m9.figshare.9862139.v132.
This project contains the following underlying data:
•    1. Optimisation of the duration of challenge for percutaneous 
infection.pzf
•    2. Optimisation of the rest period after immunisation.pzf
•    3. S. mansoni proteins gels.pptx
•    4. Half maximal antibody titres.pzf
•    5. Correlation Eggs vs Total Adults or Mature Females.pzf
•    6. Eggs per gram of liver counted across cohorts.xlsx
•    7. Cohort analysis - Individual data for antigens 10 and 
58.pzf
•    8. Repeat analysis on larger groups - Proteins 10 and 58.pzf
•    RDS-SPRN-00358.xlsx (containing all data from datasets 1, 
2, 4, 5, 7 and 8, above, in an open format).
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
Acknowledgements
The authors would like to thank Paul J. Brindley and Victoria H. 
Mann (from The George Washington University, Washington 
DC, USA) for technical support and expertise in determining 
the conditions of percutaneous infections, and the Research 
Support Facility at the Wellcome Sanger Institute for technical 
assistance.
References
1. Colley DG, Bustinduy , Secor WE, et al.: Human schistosomiasis. Lancet. 2014; 
383(9936): 2253–64.  
PubMed Abstract | Publisher Full Text | Free Full Text 
2. World Health Organization: Schistosomiasis and soil-transmitted helminthiases: 
number of people treated in 2016. Wkly Epidemiol Rec. 2017; 92(49): 749–60. 
PubMed Abstract 
3. Doenhoff MJ, Cioli D, Utzinger J: Praziquantel: mechanisms of action, resistance 
and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008; 21(6): 
659–67.  
PubMed Abstract | Publisher Full Text 
4. Tebeje BM, Harvie M, You H, et al.: Schistosomiasis vaccines: where do we 
stand? Parasit Vectors. 2016; 9(1): 528.  
PubMed Abstract | Publisher Full Text | Free Full Text 
5. McManus DP, Loukas A: Current status of vaccines for schistosomiasis. Clin 
Microbiol Rev. 2008; 21(1): 225–42.  
PubMed Abstract | Publisher Full Text | Free Full Text 
6. Merrifield M, Hotez PJ, Beaumier CM, et al.: Advancing a vaccine to prevent 
human schistosomiasis. Vaccine. 2016; 34(26): 2988–2991.  
PubMed Abstract | Publisher Full Text 
7. Siddiqui AA, Siddiqui SZ: Sm-p80-Based Schistosomiasis Vaccine: Preparation 
for Human Clinical Trials. Trends Parasitol. 2017; 33(3): 194–201.  
PubMed Abstract | Publisher Full Text | Free Full Text 
8. Riveau G, Schacht AM, Dompnier JP, et al.: Safety and efficacy of the rSh28GST 
urinary schistosomiasis vaccine: A phase 3 randomized, controlled trial in 
Senegalese children. PLoS Negl Trop Dis. 2018; 12(12): e0006968.  
PubMed Abstract | Publisher Full Text | Free Full Text 
9. Berriman M, Haas BJ, LoVerde PT, et al.: The genome of the blood fluke 
Schistosoma mansoni. Nature. 2009; 460(7253): 352–8.  
PubMed Abstract | Publisher Full Text | Free Full Text 
10. Braschi S, Borges WC, Wilson RA: Proteomic analysis of the schistosome 
tegument and its surface membranes. Mem Inst Oswaldo Cruz. 2006; 101(Suppl 
1): 205–12.  
PubMed Abstract | Publisher Full Text 
11. Braschi S, Wilson RA: Proteins exposed at the adult schistosome surface 
revealed by biotinylation. Mol Cell Proteomics. 2006; 5(2): 347–56.  
PubMed Abstract | Publisher Full Text 
12. Castro-Borges W, Dowle A, Curwen RS, et al.: Enzymatic shaving of the 
tegument surface of live schistosomes for proteomic analysis: a rational 
approach to select vaccine candidates. PLoS Negl Trop Dis. 2011; 5(3): e993. 
PubMed Abstract | Publisher Full Text | Free Full Text 
13. Protasio AV, Tsai IJ, Babbage A, et al.: A systematically improved high quality 
genome and transcriptome of the human blood fluke Schistosoma mansoni. 
PLoS Negl Trop Dis. 2012; 6(1): e1455.  
PubMed Abstract | Publisher Full Text | Free Full Text 
14. Wilson RA: Proteomics at the schistosome-mammalian host interface: any 
prospects for diagnostics or vaccines? Parasitology. 2012; 139(9): 1178–94. 
PubMed Abstract | Publisher Full Text 
15. Farias LP, Tararam CA, Miyasato PA, et al.: Screening the Schistosoma mansoni 
transcriptome for genes differentially expressed in the schistosomulum stage 
in search for vaccine candidates. Parasitol Res. 2011; 108(1): 123–35.  
PubMed Abstract | Publisher Full Text 
16. Parker-Manuel SJ, Ivens AC, Dillon GP, et al.: Gene expression patterns in larval 
Schistosoma mansoni associated with infection of the mammalian host. PLoS 
Negl Trop Dis. 2011; 5(8): e1274.  
PubMed Abstract | Publisher Full Text | Free Full Text 
17. Pearson MS, McManus DP, Smyth DJ, et al.: In vitro and in silico analysis of 
signal peptides from the human blood fluke, Schistosoma mansoni. FEMS 
Immunol Med Microbiol. 2005; 45(2): 201–11.  
PubMed Abstract | Publisher Full Text 
18. Protasio AV, Dunne DW, Berriman M: Comparative study of transcriptome 
profiles of mechanical- and skin-transformed Schistosoma mansoni 
schistosomula. PLoS Negl Trop Dis. 2013; 7(3): e2091.  
PubMed Abstract | Publisher Full Text | Free Full Text 
19. Goldring OL, Clegg JA, Smithers SR, et al.: Acquisition of human blood group 
antigens by Schistosoma mansoni. Clin Exp Immunol. 1976; 26(1): 181–7. 
PubMed Abstract | Free Full Text 
20. Smithers SR, Terry RJ, Hockley DJ: Host antigens in schistosomiasis. Proc R 
Soc Lond B Biol Sci. 1969; 171(1025): 483–94.  
PubMed Abstract | Publisher Full Text 
21. Egesa M, Hoffmann KF, Hokke CH, et al.: Rethinking Schistosomiasis Vaccine 
Development: Synthetic Vesicles. Trends Parasitol. 2017; 33(12): 918–921. 
PubMed Abstract | Publisher Full Text 
22. Cousin CE, Stirewalt MA, Dorsey CH: Schistosoma mansoni: ultrastructure of 
early transformation of skin- and shear-pressure-derived schistosomules. Exp 
Parasitol. 1981; 51(3): 341–65.  
PubMed Abstract | Publisher Full Text 
23. Fukushige M, Mitchell KM, Bourke CD, et al.: A Meta-Analysis of Experimental 
Studies of Attenuated Schistosoma mansoni Vaccines in the Mouse Model. 
Front Immunol. 2015; 6: 85.  
PubMed Abstract | Publisher Full Text | Free Full Text 
24. Dillon GP, Feltwell T, Skelton J, et al.: Altered patterns of gene expression 
underlying the enhanced immunogenicity of radiation-attenuated 
schistosomes. PLoS Negl Trop Dis. 2008; 2(5): e240.  
PubMed Abstract | Publisher Full Text | Free Full Text 
25. Wilson RA, Li XH, Castro-Borges W: Do schistosome vaccine trials in mice have 
an intrinsic flaw that generates spurious protection data? Parasit Vectors. 2016; 
9: 89.  
PubMed Abstract | Publisher Full Text | Free Full Text 
Page 14 of 21
Wellcome Open Research 2019, 4:159 Last updated: 25 MAY 2020
26. Tran MH, Pearson MS, Bethony JM, et al.: Tetraspanins on the surface of 
Schistosoma mansoni are protective antigens against schistosomiasis. Nat 
Med. 2006; 12(7): 835–40.  
PubMed Abstract | Publisher Full Text 
27. Pearson MS, Pickering DA, McSorley HJ, et al.: Enhanced protective efficacy of 
a chimeric form of the schistosomiasis vaccine antigen Sm-TSP-2. PLoS Negl 
Trop Dis. 2012; 6(3): e1564.  
PubMed Abstract | Publisher Full Text | Free Full Text 
28. Crosnier C, Protasio Anna V, Rinaldi Gabriel, et al.: A library of cell-surface and 
secreted proteins from Schistosoma mansoni identifies early serological 
markers of infection. bioRxiv. 2019: 593616.  
Publisher Full Text 
29. Bushell KM, Söllner C, Schuster-Boeckler B, et al.: Large-scale screening for 
novel low-affinity extracellular protein interactions. Genome Res. 2008; 18(4): 
622–30.  
PubMed Abstract | Publisher Full Text | Free Full Text 
30. Zenonos ZA, Rayner JC, Wright GJ: Towards a comprehensive Plasmodium 
falciparum merozoite cell surface and secreted recombinant protein library. 
Malar J. 2014; 13: 93.  
PubMed Abstract | Publisher Full Text | Free Full Text 
31. Brown MH, Barclay AN: Expression of immunoglobulin and scavenger receptor 
superfamily domains as chimeric proteins with domains 3 and 4 of CD4 for 
ligand analysis. Protein Eng. 1994; 7(4): 515–21.  
PubMed Abstract | Publisher Full Text 
32. Crosnier C, Brandt C, Rinaldi G, et al.: Data files describing the systemic 
screening of 96 Schistosoma mansoni cell surface and secreted antigens 
produced in a mammalian expression system. figshare. Dataset. 2019.  
http://www.doi.org/10.6084/m9.figshare.9862139.v1
33. Crosnier C, Wanaguru M, McDade B, et al.: A library of functional recombinant 
cell-surface and secreted P. falciparum merozoite proteins. Mol Cell Proteomics. 
2013; 12(12): 3976–86.  
PubMed Abstract | Publisher Full Text | Free Full Text 
34. Tucker MS, Karunaratne LB, Lewis FA, et al.: Schistosomiasis. Curr Protoc 
Immunol. 2013; 103: Unit 19 1.  
PubMed Abstract | Publisher Full Text 
35. Cheever AW: Conditions affecting the accuracy of potassium hydroxide 
digestion techniques for counting Schistosoma mansoni eggs in tissues.  
Bull World Health Organ. 1968; 39(2): 328–31.  
PubMed Abstract | Free Full Text 
36. Nakazawa M, Fantappie MR, Freeman GL Jr, et al.: Schistosoma mansoni: 
susceptibility differences between male and female mice can be mediated by 
testosterone during early infection. Exp Parasitol. 1997; 85(3): 233–40.  
PubMed Abstract | Publisher Full Text 
37. Watanabe H, Numata K, Ito T, et al.: Innate immune response in Th1- and Th2-
dominant mouse strains. Shock. 2004; 22(5): 460–6.  
PubMed Abstract | Publisher Full Text 
38. HogenEsch H, O'Hagan DT, Fox CB: Optimizing the utilization of aluminum 
adjuvants in vaccines: you might just get what you want. NPJ Vaccines. 2018; 
3: 51.  
PubMed Abstract | Publisher Full Text | Free Full Text 
39. Cardoso FC, Macedo GC, Gava E, et al.: Schistosoma mansoni tegument protein 
Sm29 is able to induce a Th1-type of immune response and protection against 
parasite infection. PLoS Negl Trop Dis. 2008; 2(10): e308.  
PubMed Abstract | Publisher Full Text | Free Full Text 
40. Ricciardi A, Visitsunthorn K, Dalton JP, et al.: A vaccine consisting of 
Schistosoma mansoni cathepsin B formulated in Montanide ISA 720 VG 
induces high level protection against murine schistosomiasis. BMC Infect Dis. 
2016; 16: 112.  
PubMed Abstract | Publisher Full Text | Free Full Text 
41. Zhang W, Molehin AJ, Rojo JU, et al.: Sm-p80-based schistosomiasis vaccine: 
double-blind preclinical trial in baboons demonstrates comprehensive 
prophylactic and parasite transmission-blocking efficacy. Ann N Y Acad Sci. 
2018; 1425(1): 38–51.  
PubMed Abstract | Publisher Full Text | Free Full Text 
42. Oleszycka E, Lavelle EC: Immunomodulatory properties of the vaccine adjuvant 
alum. Curr Opin Immunol. 2014; 28: 1–5.  
PubMed Abstract | Publisher Full Text 
43. Orr MT, Khandhar AP, Seydoux E, et al.: Reprogramming the adjuvant properties 
of aluminum oxyhydroxide with nanoparticle technology. NPJ Vaccines. 2019; 
4: 1.  
PubMed Abstract | Publisher Full Text | Free Full Text 
44. Collins AM: IgG subclass co-expression brings harmony to the quartet model 
of murine IgG function. Immunol Cell Biol. 2016; 94(10): 949–954.  
PubMed Abstract | Publisher Full Text 
45. Farias LP, Krautz-Peterson G, Tararam CA, et al.: On the three-finger protein 
domain fold and CD59-like proteins in Schistosoma mansoni. PLoS Negl Trop 
Dis. 2013; 7(10): e2482.  
PubMed Abstract | Publisher Full Text | Free Full Text 
Page 15 of 21
Wellcome Open Research 2019, 4:159 Last updated: 25 MAY 2020
 
Open Peer Review
   Current Peer Review Status:
Version 1
 13 November 2019Reviewer Report
https://doi.org/10.21956/wellcomeopenres.16943.r36798




































Page 16 of 21





















































Page 17 of 21















Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes




I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
 04 November 2019Reviewer Report
https://doi.org/10.21956/wellcomeopenres.16943.r36799




Page 18 of 21




































Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
Page 19 of 21
Wellcome Open Research 2019, 4:159 Last updated: 25 MAY 2020
 
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes




I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
 17 October 2019Reviewer Report
https://doi.org/10.21956/wellcomeopenres.16943.r36796















Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
Page 20 of 21
Wellcome Open Research 2019, 4:159 Last updated: 25 MAY 2020
 
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes





I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
Page 21 of 21
Wellcome Open Research 2019, 4:159 Last updated: 25 MAY 2020
